BioMark Oncology is a translationally enabled cancer therapeutics company. We are developing potential first-in-class medicines for solid tumor indications with mechanisms of action and target validation focused on whole systems biology. We believe that this approach, akin to the discovery of immune checkpoint inhibition targets, will enable the next step-function change in solid tumor efficacy and move previously overlooked but valuable targets forward. To derisk these programs, we are developing a multi-omics predictive biomarker platform measuring >1000 plasma biomarkers. We use machine learning cluster analysis to find systemic differences in responders and nonresponders in a heterogeneous patient population. This will enable host-based predictive biomarkers to complement tumor-based strategies to select the right cancer drug for the right patient.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Thousand Oaks, California 91362, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Thousand Oaks, California
Biomark Oncology Questions
Biomark Oncology's LinkedIn profile is https://www.linkedin.com/company/biomark-oncology
Biomark Oncology has
3 employees.
View email and phone details for 3
employees at Biomark Oncology.
Biomark Oncology's industry is
Biotechnology Research
Biomark Oncology's top competitors are
Nucleate Los Angeles,
Moonlight Therapeutics,
Magnify Incubator,
Lybbie,
Palate Therapeutics,
Amrixa Pharmaceuticals,
Mesh Strategic Partnerships, Keck School Of Medicine Of Usc,
Cfm Oskar Tropitzsch Gmbh,
Apt Oncology,
Revilico Inc..
Biomark Oncology's categories are Biotechnology Research
Biomark Oncology's founding year is 2021
